日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma

非转移性透明细胞肾细胞癌新辅助治疗中纳武利尤单抗的免疫调节反应

Nirmish Singla # ,Thomas R Nirschl # ,Aleksandar Z Obradovic ,Eugene Shenderov ,Kara Lombardo ,Xiaopu Liu ,Alice Pons ,Jelani C Zarif ,Steven P Rowe ,Bruce J Trock ,Hans J Hammers ,Trinity J Bivalacqua ,Phillip M Pierorazio ,Julie S Deutsch ,Tamara L Lotan ,Janis M Taube ,Yasser M A Ged ,Michael A Gorin ,Mohamad E Allaf ,Charles G Drake

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

单药抗程序性死亡-1 (MDX-1106) 治疗难治性实体瘤的 I 期研究:安全性、临床活性、药效学和免疫学相关性

Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, William H Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M Salay, Tracee L McMiller, Marta M Gilson, Changyu Wang, Mark Selby, Janis M Taube, Robert Anders, Lieping Chen, Alan J Korman, Drew M Pardoll, Israel Lowy, Suza